Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 18th 2015

Joy Larsen Haidle on How the Genetic Testing Landscape Has Changed

After the Supreme Court struck down gene patents, not only is more genetic testing is being offered, but the technology of the test has expanded to the benefit of patients, said Joy Larsen Haidle, MS, CGC, president of the National Society of Genetic Counselors.

November 18th 2015

Surabhi Dangi-Garimella, PhD

This is the company's third biosimilar Biologics License Application in the United States.

November 17th 2015

Tagrisso Approved, but Can Patients With EGFR-Mutant NSCLC Afford It?

Surabhi Dangi-Garimella, PhD

The drug is estimated to cost close to $13,000 per month.

November 17th 2015

FDA Regulation of LDTs: A Report Justifies the Need for It

Surabhi Dangi-Garimella, PhD

It is time to regulate laboratory-developed tests that cost Medicare $9.7 billion in the year 2012 alone.

November 16th 2015

Daratumumab Approval Yields the First Monoclonal Antibody, and Another Option, in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The drug was approved based on results of 2 open-label studies that showed reduction in tumor burden of patients who had previously received multiple lines of therapy.

November 16th 2015

Should We Trust Screening Age Recommendations in Cancer?

Surabhi Dangi-Garimella, PhD

When to screen and how to screen remain controversial issues in prostate cancer.

November 14th 2015

This Week in Managed Care: November 14, 2015

This week in managed care the top stories include pivotal results from the SPRINT study on blood pressure, an analysis on how states successfully enrolled consumers in the insurance marketplace, and experts discuss value-based care.

November 13th 2015

Creating a Supportive Environment Through the Use of Palliative Care

Laura Joszt, MA

Panelist discuss early referral to palliative care, enduring misconceptions, culture considerations, and more at the Fall Managed Care Forum 2015.

November 12th 2015

Smoking Rates Declining but Disparities Evident: CDC Report

Surabhi Dangi-Garimella, PhD

According to the CDC, while smoking rates are seeing a steady decline, rates for uninsured and adults on Medicaid are more than twice those for adults with private health insurance.

November 12th 2015

Learning From Your Daughters About Cancer Prevention

Surabhi Dangi-Garimella, PhD

A study in The European Journal of Public Health finds conversation on preventive vaccination against HPV can motivate participation in preventive screening for cervical cancer.

November 11th 2015

Oral Contraceptives Can Improve Outcomes in Ovarian Cancer

Surabhi Dangi-Garimella, PhD

A retrospective study conducted at the Mayo Clinic found improved OS and PFS in ovarian cancer patients with a history of oral contraceptive use.

November 11th 2015

Narrow Network and Insolvent Exchange Plan Leaves Cancer Patients Scampering for Options

Surabhi Dangi-Garimella, PhD

A forced closing of Health Republic Insurance of New York has left many in need of immediate coverage.

November 10th 2015

Dr Crystal S. Denlinger Discusses Potential Cardiotoxicity Concerns for Cancer Survivors

Historically cancer survivorship programs have not emphasized cardiac follow-up and there is not a lot of long-term data on cardiac toxicity in patients who received certain drugs, but that is changing as patients live longer and fuller lives after treatment, explained Crystal S. Denlinger, MD, from the Fox Chase Cancer Center in Philadelphia.

November 10th 2015

Cobimetinib/Vemurafenib Receives FDA Approval in Advanced Melanoma

AJMC Staff

The approval comes after a priority review of the combination that blocks activity of 2 MAPK proteins: BRAF and MEK.

November 10th 2015

A Cancer Prevention Trial Identifies Predictive Biomarker in Oral Cancer Development

Surabhi Dangi-Garimella, PhD

Published in JAMA Oncology, the trial found an association between loss of heterozygosity and cancer-free survival in patients who had been diagnosed with oral premalignant lesions.

November 9th 2015

Medi-Cal Cancer Patients Perform Worse Than Those on Other Insurance, UC Davis Study

Surabhi Dangi-Garimella, PhD

Heterogeneity in quality of care and cancer patient survival based on insurance coverage are the highlight of a report by researchers at the Institute for Population Health Improvement at the University of California Davis.

November 9th 2015

Exceptional Response in Brain Tumor Patient Instills Confidence in Personalized Medicine

Surabhi Dangi-Garimella, PhD

Treatment of a recurrent brain tumor harboring a BRAF mutation with an inhibitor approved for melanoma resulted in dramatic tumor shrinkage.

November 8th 2015

Advancing the Wave of Democratization of Cancer Care

Emmanuel F. Petricoin III, PhD

Democratizing the complex field of cancer care is not easy. We are providing patients with key information that their own cancer is unique and needs to be treated as such, but there is a great deal of work to be done in putting that knowledge to work.

November 7th 2015

This Week in Managed Care: November 7, 2015

This week in managed care Kentucky elected a new governor who could bring big changes to the state's Medicaid program, researchers reported that costs of dementia in the last 5 years of life surpass even cancer, and the latest Hospital Safety Score report was released.

November 6th 2015

Plavix Does Not Increase the Risk of Cancer

Surabhi Dangi-Garimella, PhD

The FDA's meta-analyses, following results of the DAPT trial in 2014, have found no association between treatment with the blood thinner clopidogrel (Plavix) and increased incidence of, or death due to, cancer.

November 6th 2015

5 Things to Know About Value in Healthcare

Surabhi Dangi-Garimella, PhD

From CMS to private health plans, professional healthcare organizations to patients and advocacy groups, the discussion nowadays seems to end up with value.

November 5th 2015

Linda House on Considering How a Patient's Needs May Change

As patients with cancer live longer and the disease becomes a chronic disease for many, it becomes important for providers to understand how the needs of the patient change from being newly diagnosed to active therapy to long-term therapy, explained Linda House, president of the Cancer Support Community.

November 5th 2015

Study Yields Path to Smart Treatment in Prostate Cancer

Surabhi Dangi-Garimella, PhD

A blood test that can detect mutations in the androgen receptor can predict response to abiraterone in prostate cancer.

November 5th 2015

Optimizing Hashtags to Organize Health Information on Twitter

Surabhi Dangi-Garimella, PhD

New research, published in JAMA Oncology, presents evidence of how the use of disease-specific hashtags on Twitter can help those with common interests collectively share information.

November 4th 2015

Prostate Cancer Study Rekindles Price Transparency Debate

Surabhi Dangi-Garimella, PhD

Published in the journal Cancer, the study evaluated the short-term and long-term costs of treating patients with low-risk prostate cancer across the entire care spectrum.

November 4th 2015

Contraceptive Procedure Can Reduce the Risk of Specific Subtypes of Ovarian Cancer

Surabhi Dangi-Garimella, PhD

According to a study published in The International Journal of Cancer, tubal ligation can reduce the risk of serous, endometrioid, and clear cell ovarian carcinoma.

November 4th 2015

Kentucky's New Governor Could Change the Terms of Medicaid Expansion

Mary K. Caffrey

Departing Governor Steve Beshear's full embrace of the Affordable Care Act brought health coverage to 500,000 people in Kentucky, including many who had never had insurance. Preventive services increased by more than 100%.

November 3rd 2015

Antihypertensive Drug Could Be an Inexpensive Anticancer Agent

Surabhi Dangi-Garimella, PhD

A new research study published in the Journal of Dermatology has found that propranolol, a commonly used antihypertensive agent, could substantially reduce proliferation of angiosarcoma.

November 3rd 2015

ASCO Confirms Support for the President's Nominee for FDA Commissioner

AJMC Staff

Fifty organizations, including the American Society of Clinical Oncology, have expressed their confidence in Robert Califf, MD, to lead the FDA.

November 3rd 2015

Impact of ASCO Results Hold: Pembrolizumab Granted Breakthrough in Advanced CRC

Surabhi Dangi-Garimella, PhD

After melanoma and non-small cell lung cancer, the FDA has granted Breakthrough Therapy status to pembrolizumab in advanced colorectal cancer patients with mismatched repair deficiency.

...

118 119 120 121 122 123 124 125 126

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions